Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30060059 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM3GPR119RET | |
| SCHEMBL20722688 | 0.94 | JAK1 (0.39) | CHRM2CHRM1CHRM3GPR119RET | |
| SCHEMBL20722417 | 0.94 | JAK1 (0.39) | CHRM2CHRM1CHRM3GPR119RET | |
| SCHEMBL30060077 | 0.94 | JAK1 (0.39) | CHRM2CHRM1CHRM3GPR119RET | |
| SCHEMBL21704014 | 0.83 | MAPT (0.42) | GPR119DPP4 | |
| SCHEMBL30059886 | 0.83 | MAPT (0.42) | GPR119DPP4 | |
| SCHEMBL30061814 | 0.83 | MAPT (0.42) | GPR119DPP4 | |
| SCHEMBL20732122 | 0.83 | MAPT (0.42) | GPR119DPP4 | |
| SCHEMBL20722889 | 0.79 | — | — | |
| SCHEMBL21685700 | 0.78 | JAK1 (0.41) | CHRM2CHRM1CHRM3GPR119RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CHRM2 4456/4885CHRM1 4386/4885CHRM3 4232/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | CHRM2 4456/4885CHRM1 4386/4885CHRM3 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.